Insilico Medicines尽管损失了19.22B美元,却在香港最大的生物技术IPO筹集了293M美元,在全球推广AI驱动的药物发现。 Insilico Medicine, despite a $19.22B loss, raised $293M in Hong Kong’s largest biotech IPO to expand AI-driven drug discovery globally.

香港上市生物技术公司Insilico Medicines(Insilico Medicines)在政府投资的支持下, 正在利用其AI Pharma. Insilico Medicine, a Hong Kong-listed biotech firm backed by government investment, is leveraging its AI platform Pharma.AI to accelerate drug discovery, reducing development time from years to months with a high success rate in trials. 该公司扩大在中国的张江中心,拥有23名药物候选人,其中两名在第二阶段,并与Fosun Pharma和Eli Lilly结成伙伴关系。 The company, expanding in China’s Zhangjiang hub, has 23 drug candidates, two in Phase II, and partnerships with Fosun Pharma and Eli Lilly. 尽管在2025年初损失了192.2亿美元,但它在香港最大的生物技术投资促进组织筹集了2.93亿美元,计划将48%用于研发和全球扩张,包括AI中心,以帮助中东等国家通过负担得起的AI工具开发本土药品。 Despite a $19.22 billion loss in early 2025, it raised $293 million in Hong Kong’s largest biotech IPO, planning to use 48% for R&D and global expansion, including AI hubs to help countries like those in the Middle East develop homegrown medicines via affordable AI tools.